Drug survival of adalimumab biosimilars in real world treatment of psoriasis: a Spanish multicenter study.

In Spanish real world clinical practice, drug survival of adalimumab biosimilar is longer in males, younger patients, patients with psoriatic arthritis, and patients who switch from adalimumab originator (compared to biologic-naïve patients who start adalimumab biosimilar as their first biologic). This article is protected by copyright. All rights reserved.